Impact of Combining Immune Checkpoint Inhibitors with Chemotherapy in the Management of Advanced Serous Endometrial Adenocarcinoma
Hamadoun Traoré *
Department of Medical Oncology, Mohammed V Military Training Hospital, Morocco.
Andy J Kouanga
Department of Medical Oncology, Mohammed V Military Training Hospital, Morocco.
Choukri Elm’hadi
Department of Medical Oncology, Mohammed V Military Training Hospital, Morocco.
Ait Sahel Omar
Department of Nuclear Medicine, Mohammed V Military Training Hospital, Morocco.
Rachid Tanz
Department of Medical Oncology, Mohammed V Military Training Hospital, Morocco.
Hassan Errihani
National Institute of Oncology, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Chemo-immunotherapy is a relatively recent approach to the treatment of advanced or relapsed endometrial cancer. The aim of these therapies is to remove immune suppression, enabling the immune system to better recognise and destroy cancer cells. We report a clinical case of stage 4 endometrial cancer in a 69-year-old patient with several commorbidities in whom we obtained a complete response after four cycles of paclitaxel+carboplatin combined with pembrolizumab followed by maintenance immunotherapy. Immunotherapy combined with chemotherapy is a relatively recent approach to the treatment of advanced or relapsed endometrial cancer. This case report demonstrates the importance of adding immunotherapy to chemotherapy in the management of advanced endometrial cancer.
Keywords: Advanced endometrial cancer, immunotherapy, chemotherapy